We can’t show the full text here under this license. Use the link below to read it at the source.
The role of glucagon-like peptide-1 receptor agonists in weight regain treatment or prevention after bariatric surgery: a systematic review and meta-analysis
Glucagon-like peptide-1 drugs for preventing or treating weight regain after weight-loss surgery: a review and analysis
AI simplified
Abstract
A meta-analysis of 769 participants found a significantly greater in those treated with (GLP-1RAs) compared to placebo.
- Weight loss (WL) was greater in the GLP-1RAs group with a standardized mean difference of 0.82.
- In participants who started GLP-1RAs treatment within 6 months post-surgery, WL was also higher (standardized mean difference of 0.79).
- Adverse events associated with GLP-1RAs were mostly gastrointestinal, particularly nausea, which occurred more often in the treatment group (odds ratio of 2.01).
- Approximately 20-25% of patients experience (WR) after bariatric surgery, highlighting the need for effective management strategies.
AI simplified
Key numbers
0.82
Increase in
Standardized mean difference (SMD) for GLP-1RAs vs. placebo.
2.01
Higher Incidence of Nausea
Odds ratio (OR) for nausea in GLP-1RAs group vs. placebo.
0.79
in Short-Term Treatment
Standardized mean difference (SMD) for treatment durations ≤ 6 months.